glp-1 obesity drug news today 2025-10-20 Weight Loss Market Size, Share The GLP-1 Access Gap: Mapping

3 Results of reduced GIP receptor activation in humans Some GIP receptor antagonists have contributed to the elucidation of the physiological properties of endogenous GIP

[Google Scholar] 2.Dungan K, DeSantis A Glucagon-like peptide 1-based therapies for the treatment of type 2 diabetes mellitus

Tirzepatide: a novel, first-in-class, dual GIP/GLP-1 receptor agonist

Y., Yin, H., Hillaire-Buys, D., Barkun, A., & Azoulay, L

Current medical nutrition therapy guidelines advocate for personalized, flexible, and healthy eating patterns rather than a one-fits-all approach [227]

These are not semaglutide side effects and should prompt evaluation